Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design

2:00 pm - Wednesday 14th October 2026

Integrating ADC MoA, target biology, payload dynamics, ADC/ICI disposition, and tumor–immune interactions with key clinical biomarkers
Iteratively tuning QSP model with preclinical and clinical data to predict PK, efficacy and safety
Simulating heterogeneous virtual populations to evaluate dosing strategies and therapeutic performance across ADCs and combinations

Speakers:

Sheetal Panday

Sheetal Panday

Associate Director - Quantitative Pharmacology & Pharmacometrics, Immuno Oncology

Merck & Co